Breakthroughs are accelerating across therapeutics, data platforms, regulatory systems and business models. Yet challenges remain in how we develop and scale innovation within an increasingly complex landscape. Addressing these challenges requires collaboration across the life science ecosystem.
ON Helix brings together this breadth and diversity, connecting biotech innovators, pharma, academia, service providers and investors to create an environment for meaningful peer-to-peer learning and deal-making. It is through these interactions that innovation is accelerated and ultimately translated into better patient outcomes.
This year’s programme highlights key debates and emerging opportunities, including:
Next-generation RNA therapeutics – According to PitchBook data, venture capital in RNA therapeutics in biotechnology exceeded £250 million in 2025, reflecting 17% growth from 2024. At ON Helix, Cartesian Therapeutics will showcase the next generation of RNA therapies beyond COVID, while AstraZeneca will highlight collaborations that are accelerating the translation of RNA therapeutics into the clinic. The $12 billion acquisition of Avidity Biosciences by Novartis in late 2025 further highlights the value that big pharma places on RNA modalities.
Platform-driven R&D - Nicole Mather, Chair of the Wellcome Genome Campus Science and Technology Advisory Group, will provide a keynote address on the rise of software-enabled platforms transforming R&D, aligned with over £600 million of capital invested into drug discovery software in 2024, according to PitchBook data.
Alternatives to animal testing - CN Bio, who recently secured $21 million in Series B financing to expand its organ-on-a-chip platform, will highlight alternatives to animal testing, demonstrating how these models are reshaping preclinical development. The company will also share insights on whether the industry is approaching an inflection point, including regulatory and stakeholder responses. Companies like Qureator, whose Curiochips platform has enabled FDA IND approval, further illustrate momentum in this field. Meanwhile, PPD Clinical Research Services will provide insights on innovations in adaptive trial designs enabling faster transitions through clinical phases.
Through expert-led discussions and a programme built around ample networking opportunities alongside the exhibition, ON Helix offers a forum for exploring emerging trends, fostering partnerships and highlighting your ogranisation’s role in the innovation ecosystem.
Stay tuned for more speaker announcements coming soon!
Be part of the conversation and sign up today! – www.onhelix.com